Johnson & Johnson (JNJ) net income: $26.8B
Johnson & Johnson reported a net income of $26.8B for the year ended Dec 28, 2025, up 90.6% from $14.1B a year earlier.
From Johnson & Johnson's filings with the SEC · Read the filing · JNJ stock page
Johnson & Johnson net income by year
#11 of 3,748 US companies by net income · See the full ranking
| Year ended | Net income | Change |
|---|---|---|
| Dec 28, 2025 | $26.8B | +91% |
| Dec 29, 2024 | $14.1B | -60% |
| Dec 31, 2023 | $35.2B | +96% |
| Jan 1, 2023 | $17.9B | -14% |
| Jan 2, 2022 | $20.9B | – |
Net income of similar companies
Companies in the same industry as Johnson & Johnson, by SEC industry code, with the closest net income. Each name opens the same page for that company.
| Company | Net income, latest year | Year ended |
|---|---|---|
| Johnson & Johnson | $26.8B | Dec 28, 2025 |
| Eli Lilly | $20.6B | Dec 31, 2025 |
| Merck | $18.3B | Dec 31, 2025 |
| Pfizer | $7.8B | Dec 31, 2025 |
| Bristol Myers Squibb | $7.1B | Dec 31, 2025 |
| Abbott Laboratories | $6.5B | Dec 31, 2025 |
| Regeneron Pharmaceuticals | $4.5B | Dec 31, 2025 |
Questions and answers
What is Johnson & Johnson's net income?
Johnson & Johnson reported a net income of $26.8B for the year ended Dec 28, 2025, up 90.6% from $14.1B a year earlier.
Numbers as reported in Johnson & Johnson's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology